Related Experiment Videos
Cyclobutane derivatives as potent NK1 selective antagonists
Michelle Laci Wrobleski1, Gregory A Reichard, Sunil Paliwal
1Chemical Research Department, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Bioorganic & Medicinal Chemistry Letters
|May 10, 2006
Summary
Novel cyclobutane derivatives show high affinity for neurokinin-1 (NK1) receptors. These potent NK1 receptor antagonists are effective centrally after oral administration, with syntheses detailed.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Neurokinin-1 (NK1) receptors are implicated in various physiological processes.
- Development of selective NK1 receptor antagonists is a key therapeutic goal.
Purpose of the Study:
- To describe novel cyclobutane derivatives as potential NK1 receptor antagonists.
- To evaluate the in vitro and in vivo efficacy of these compounds.
Main Methods:
- Synthesis of a series of novel cyclobutane derivatives.
- In vitro binding assays to determine affinity for NK1 receptors.
- In vivo studies to assess central NK1 receptor inhibition after oral administration.
Main Results:
- Several cyclobutane derivatives demonstrated high in vitro binding affinity (Ki <= 1 nM).
- Compounds showed potent inhibition of central NK1 receptors following oral dosing.
- Synthetic routes for the novel compounds were successfully established.
Conclusions:
- The described cyclobutane derivatives represent a promising class of potent and selective NK1 receptor antagonists.
- These compounds hold potential for therapeutic applications targeting NK1 receptor pathways.